DelveInsight’s “Chronic Venous Insufficiency Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Chronic Venous Insufficiency, historical and forecasted epidemiology as well as the Chronic Venous Insufficiency market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Chronic Venous Insufficiency Market Share @ Chronic Venous Insufficiency Market Outlook

Key Takeaways from the Chronic Venous Insufficiency Market Report

• In the 7MM, the US accounted for the highest number of Chronic Venous Insufficiency Prevalent Cases with nearly 6.2 million in 2020.
• In the 7MM, the total Chronic Venous Insufficiency Prevalent Cases were 463 million in 2020,
• Among EU4 and the UK, Germany accounted for the highest number of cases of Chronic Venous Insufficiency, followed by UK, whereas Spain occupied the bottom of the ladder.
• According to DelveInsight’s epidemiology model for CVD, the C1 stage had the highest diagnosed prevalence in the United States.
• The leading Chronic Venous Insufficiency Companies such as Verigraft AB, enVVeno Medical Corporation, Theraclion and others.
• Promising Chronic Venous Insufficiency Pipeline Therapies such as Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus and others.

Stay ahead in the Chronic Venous Insufficiency Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Venous Insufficiency Treatment Market

Chronic Venous Insufficiency Epidemiology Segmentation in the 7MM

For the epidemiology forecast model of CVI, the total Chronic Venous Insufficiency prevalence was first calculated for the adult population. Since not all patients with CVD are diagnosed, using the disease diagnosis rate, the number of diagnosed prevalent cases of CVD was determined. From this segmentation, the diagnosed prevalent cases specific to CVI were derived by aggregating the total cases within stages C3–C6 of the CEAP classification. Subsequently, these CVI cases were further segmented to ascertain the number of cases specific to each gender. in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Download the report to understand which factors are driving Chronic Venous Insufficiency Epidemiology trends @ Chronic Venous Insufficiency Prevalence

Chronic Venous Insufficiency Marketed Drugs

• Venclose System: BD

The Venclose System consists of two main components: 1) Maven Catheter with integrated cable connector and, 2) digiRF Generator which delivers radiofrequency (RF) energy to the Maven catheter. The Maven catheter is a sterile single-use disposable medical device for endovenous radiofrequency ablation. The primary components of the catheter include the shaft, handle and integrated connector cable. The catheter shaft is 6 French (6F = 2.0 mm in diameter) in profile, with an insertable length of 40 cm and a 0.5 cm heating coil. The catheter is energized by the digiRF Generator which is a multi-voltage energy delivery system with touchscreen control that automatically sets the non-adjustable treatment parameters for the catheter. The Venclose Maven System (digiRF Generator and Maven Catheter) uses resistive radiofrequency ablation (via energy delivered to heat the wall of an incompetent vein) with temperature-controlled RF energy, and an already widely accepted procedure to cause irreversible luminal occlusion. This is followed by fibrosis and ultimately resorption of the vein. The Venclose Maven System (digiRF Generator and Maven Catheter) supports an optional foot pedal.

Chronic Venous Insufficiency Emerging Drugs

• P-TEV: Verigraft AB

P-TEV (Personalized Tissue-Engineered Veins) is an advanced therapy medicinal product (ATMP) being developed by Verigraft as an alternative to autologous or synthetic vascular grafts used in reconstructive vein surgery. The P-TEV drug substance consists of an extracellular matrix (ECM) scaffold in the form of a decellularized (DC) allogeneic vein scaffold which is populated with autologous components from the patient’s own peripheral whole blood (PWB) in an ATMP manufacturing process performed under GMP. As the allogeneic immunogenic material has been removed from the donated vein segment by DC and as the perfusion uses autologous PWB, no immunosuppression is required.

To learn more about Chronic Venous Insufficiency Treatment guidelines, visit @ Chronic Venous Insufficiency Clinical Trials Assessment

Chronic Venous Insufficiency Companies

Verigraft AB, enVVeno Medical Corporation, Theraclion and others.

Chronic Venous Insufficiency Market Outlook

In the Chronic Venous Insufficiency pipeline among the emerging candidates, SONOVEIN, which is a robotic solution for non-invasive echotherapy treatment using high-intensity focused ultrasound (HIFU) technology. It operates independently without the need for additional accessories such as guide wires, puncture kits, or catheters. The device is being evaluated in a VEINRESET study, which is now transitioning into a 12-month follow-up period, with results projected for release by 2025. The company plans to file the market approval application with the FDA once the study report is available in the second half of 2025.

Learn more about the FDA-approved drugs for Chronic Venous Insufficiency @ Drugs for Chronic Venous Insufficiency Treatment

Scope of the Chronic Venous Insufficiency Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Venous Insufficiency Companies- Verigraft AB, enVVeno Medical Corporation, Theraclion and others.
• Chronic Venous Insufficiency Pipeline Therapies- Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus and others.
• Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency Market Drivers and Barriers
• Chronic Venous Insufficiency Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Chronic Venous Insufficiency Market Report Introduction

3. Chronic Venous Insufficiency Market Overview at a Glance

4. Chronic Venous Insufficiency Epidemiology and Market Methodology

5. Chronic Venous Insufficiency Executive Summary

6. Key Events

7. Chronic Venous Insufficiency Market Disease Background and Overview

8. Patient Journey

9. Chronic Venous Insufficiency Epidemiology and Patient Population

10. Chronic Venous Insufficiency Marketed Drugs

11. Chronic Venous Insufficiency Emerging Drugs

12. Chronic Venous Insufficiency Emerging Devices

13. Chronic Venous Insufficiency: Market Analysis

14. Key Opinion Leaders’ Views

15. Chronic Venous Insufficiency SWOT Analysis

16. Chronic Venous Insufficiency Unmet Needs

17. Chronic Venous Insufficiency Market Drivers

18. Chronic Venous Insufficiency Market Barriers

19. Chronic Venous Insufficiency Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-venous-insufficiency-market